Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
Canopy Growth Corporation has successfully acquired Ace Valley, a prominent cannabis brand in Ontario, known for its 'Ready to Enjoy' products. This acquisition is anticipated to enhance Canopy's brand portfolio and leverage its distribution capabilities, aiming for nationwide expansion in Canada. Ace Valley's strong presence among millennial and Gen-Z consumers complements Canopy's existing offerings, enabling potential revenue growth. Canopy expects to optimize production and realize cost synergies, further solidifying its position in the cannabis market.
Canopy Growth Corporation (NASDAQ: CGC) announced a US$750 million senior secured term loan agreement with King Street Capital Management on March 18, 2021. The loan, with no amortization payments and maturing on March 18, 2026, allows for an additional US$500 million in incremental debt. The funds will enhance Canopy's balance sheet and support investments in growth initiatives, acquisitions, and capital expenditures. Following this financing, Canopy's estimated cash position as of December 31, 2020, would have been approximately CAD$2.5 billion.
Canopy Growth Corporation (TSX: WEED, NASDAQ: CGC) announced that EVP & CFO Mike Lee will participate in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021, at 9:30 AM ET. The event will be available via live webcast on the company’s website, with a replay option until September 7, 2021.
Canopy Growth is a leader in the cannabis sector, offering a variety of cannabinoid-based products globally. Their brands include Spectrum Therapeutics and BioSteel, and they have partnerships with major companies like Constellation Brands.
Canopy Growth Corporation (NASDAQ: CGC) has launched its CBD-infused sparkling water brand, Quatreau, in the U.S., following its success in Canada. This ready-to-drink beverage contains 20 mg of hemp-based CBD, comes in four flavors, and has an MSRP of $3.99 per can. The product aims to cater to U.S. consumers looking for a zero-sugar, low-calorie option. Canopy Growth's President believes the beverage will enhance growth in the CBD market. The launch coincides with an astrology-themed marketing campaign, partnering with celebrity astrologist Susan Miller.
Canopy Growth has completed a plan of arrangement under Ontario's Business Corporations Act.
The company now holds 38,890,570 exchangeable shares and 22,474,130 warrants in TerrAscend, representing approximately 20% of TerrAscend's shares on a fully-diluted basis. This move strengthens Canopy's U.S. exposure amidst potential cannabis reform. Additionally, Canopy Growth increased its ownership in Vert Mirabel from about 41% to approximately 55%. The arrangement also resulted in annual cash savings of approximately $2.9 million by terminating a royalty agreement.
Canopy Rivers has received court approval for a plan of arrangement involving Canopy Growth (CGC), wherein Rivers will transfer three portfolio assets in exchange for approximately $115 million in cash and 3.65 million shares of Canopy Growth. The arrangement, expected to finalize by February 23, 2021, includes the cancellation of all voting shares of Rivers held by Canopy Growth. Following this, Canopy Rivers will rebrand to RIV Capital Inc..
Canopy Rivers reported a comprehensive income of $82.2 million for Q3 2021, significantly attributed to the increased value of its investment in TerrAscend. The company finalized a transformative transaction with Canopy Growth (CGC), expected to close by late February, enhancing its strategic position for entering the U.S. cannabis market. Despite a net operating loss of $9.6 million for the quarter, Canopy Rivers anticipates stronger financial stability and growth opportunities following this deal. The company is also advancing its restructuring efforts with PharmHouse.
Canopy Rivers reported a comprehensive income of $82.2 million for Q3 2021, driven by significant gains in its investment in TerrAscend. The company announced a transformative transaction with Canopy Growth to sell interests valued at $115 million, expected to close by the end of February 2021. This transaction is projected to enhance liquidity and strategic positioning for entry into the U.S. cannabis market. Despite a net operating loss of $9.6 million, the company's prior challenges seem to be resolving as it anticipates profitable growth following the deal.
Canopy Growth Corporation reported record net revenue of $153 million for Q3 FY 2021, marking a 23% increase year-over-year. Canadian recreational market share rose to 15.7%, boosted by improved commercial execution. The company is implementing a cost savings program aimed at achieving profitability in the second half of FY 2022. However, a net loss of $829 million was attributed to impairment and restructuring charges. The company projects a 40%-50% CAGR in net revenue from FY 2022 to FY 2024, amid positive trends in both domestic and international cannabis markets.
Canopy Animal Health, a division of Canopy Growth (NASDAQ:CGC), has launched SurityPro, a new line of scientifically formulated CBD soft chews and oils for dogs. These products aim to enhance health and well-being, offering solutions for calm behavior, joint flexibility, and healthy aging. The SurityPro line includes five formulas with varying CBD concentrations, all adhering to NASC quality standards. The launch follows extensive research and collaboration with veterinarians. Additionally, Canopy partnered with Martha Stewart to offer another CBD pet product range.